References
- Stephensson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173�81.
- Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomogram (Partin Tables) for the new millennium. Urology 2001; 58: 843�8.
- Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528�37.
- Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate specific antigen. The clinical value of percent free prostate specific antigen. Urol Clin North Am 1997; 24: 353�65.
- Roehl KA, Antenor JAV, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4 ng/ml range. J Urol 2002; 168: 922�5.
- Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of the transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4 ng/mL. Urology 1999; 54: 517� 22.
- Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542�7.
- Vesella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, et al. Probability of prostate cancer detection based on results of a multicenter study using AxSYM free PSA and total PSA. Urology 2000; 55: 909�24.
- Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159: 1238�42.
- Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter trial. J Urol 1999; 162: 1346�51.
- Morote J, Encabo G, de Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur Urol 2000; 38: 225�9.
- Okegawa T, Noda H, Ohta M, Kato M, Nutahara K, Higashihara E. Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer. Int J Urol 2001; 8: 438�43.
- Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997; 157: 544�7.
- Melchior SW, Noteboom J, Gillitzer R, Lange PH, Blumenstein BA, Vessella RL. The percentage of free prostate specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU Int 2001; 88: 221�5.
- Tombal B, Querton M, de Nayer P, Sauvage P, Cosyns JP, Feyaerts A, et al. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology 2002; 59: 256�60.
- Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002; 167: 1306�9.
- Mitrunen K, Pettersson K, Piironen T, Bjo�rk T, Lilja H, Lo�vgren T. Dual-label one step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41: 1115�20.
- Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50�66 years. Implications for sampling order. Eur Urol 2001; 39: 655� 60.
- Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68: 821�8.
- Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 2428�34.
- Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528�34.